IRF9 and bladder transitional cell carcinoma: IRF9 demonstrated protective effects with improved PFS (P = 0.022), DFS (P = 0.00063), and DSS (P = 0.0085) in TCGA-BLCA and better OS in IMvigor210 (P = 0.00085).